Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Accounts Payables (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Accounts Payables for 5 consecutive years, with $627000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 72.64% to $627000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $627000.0, a 72.64% decrease, with the full-year FY2024 number at $1.2 million, down 62.34% from a year prior.
  • Accounts Payables was $627000.0 for Q3 2025 at Lyra Therapeutics, down from $680000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.1 million in Q3 2023 to a low of $627000.0 in Q3 2025.
  • A 5-year average of $2.5 million and a median of $2.6 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: soared 150.78% in 2023, then crashed 86.32% in 2025.
  • Lyra Therapeutics' Accounts Payables stood at $3.1 million in 2021, then decreased by 16.29% to $2.6 million in 2022, then grew by 19.69% to $3.1 million in 2023, then tumbled by 62.34% to $1.2 million in 2024, then crashed by 46.82% to $627000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Accounts Payables are $627000.0 (Q3 2025), $680000.0 (Q2 2025), and $725000.0 (Q1 2025).